home ver. 2.3. site index contact us

Company Overview
Annual / Quarterly Reports
Corporate Governance
Dividend History
E-mail Alerts
Investor FAQs
Financial Highlights
Historical Price Lookup
Investor Publications
Investment Calculator
Presentations / Webcast
Press Releases
SEC Filings
Stock Chart

Shareholder Services

For Investors

The information on this site is intended only for investors. All visitors should read the important advisory information by clicking here.

< Back

Current shareholders of record can obtain information about Schering-Plough stock through the Bank of New York Stock Transfer Web site at www.stockbny.com. As Schering-Plough's registrar and transfer and dividend disbursing agent, The Bank of New York provides information on:

• How to enroll in the reinvestment plan
• How to obtain duplicate statements
• How to withdraw, sell or transfer shares

The site also offers up-to-the-minute stock quotes, a glossary of terms and frequently asked questions.

Shareholders can also check account balances, market valuation, and transaction history, request information, and receive transfer instructions by forwarding e-mail requests to shareowner—svcs@bankofny.com, or by contacting The Bank of New York at the following address or telephone number:

The Bank of New York
Shareholder Relations Department
P.O. Box 11258
Church Street Station
New York, NY 10286-1258
Telephone: Toll free (877) 429-1240 or (610) 382-7833 for calls outside the U.S.

Address change requests should be directed to:

The Bank of New York
Receive and Deliver Department
P.O. Box 11002
Church Street Station
New York, NY 10286-1002

Links:

PDF Proxy Statement
Annual Reports
Systematic Investment Program
Featured Product

Click here for more information about COPPERTONE.

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
 
                                      © 2003-2008 Schering-Plough Corporation.
                 Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough